Literature DB >> 9990040

G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation.

J L Dai1, R K Bansal, S E Kern.   

Abstract

The tumor suppressor Smad4/Dpc4 is a transcription activator that binds specific DNA sequences and whose nuclear localization is induced after exposure to type beta transforming growth factor-like cytokines. We explored an inducible system in which Smad4 protein is activated by translocation to the nucleus when cell lines that stably express wild-type or mutant Smad4 proteins fused to a murine estrogen receptor domain are treated with 4-hydroxytamoxifen. This induced Smad4-mediated transcriptional activation and a decrease in growth rate, attributable to a cell cycle arrest at the G1 phase and an induction of apoptosis. A tumor-derived mutation (Arg-100 --> Thr) affecting a residue critical for DNA-binding demonstrated an "oncogenic" phenotype, having decreases in both the G1 fraction and apoptosis and, consequently, an augmentation of population growth. This model should be useful in the exploration and control of components that lie further downstream in the Smad4 tumor-suppressor pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9990040      PMCID: PMC15479          DOI: 10.1073/pnas.96.4.1427

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Reversible inhibition of mammary gland growth by transforming growth factor-beta.

Authors:  G B Silberstein; C W Daniel
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

Review 2.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

3.  Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells.

Authors:  P Martikainen; N Kyprianou; J T Isaacs
Journal:  Endocrinology       Date:  1990-12       Impact factor: 4.736

4.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

Authors:  J Bartek; R Iggo; J Gannon; D P Lane
Journal:  Oncogene       Date:  1990-06       Impact factor: 9.867

5.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

6.  Characterization of the inhibitory effects of transforming growth factor-beta on a human colon carcinoma cell line.

Authors:  N M Hoosein; D E Brattain; M K McKnight; A E Levine; M G Brattain
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

7.  Structural rearrangement of the retinoblastoma gene in human breast carcinoma.

Authors:  A T'Ang; J M Varley; S Chakraborty; A L Murphree; Y K Fung
Journal:  Science       Date:  1988-10-14       Impact factor: 47.728

8.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.

Authors:  E W Thompson; S Paik; N Brünner; C L Sommers; G Zugmaier; R Clarke; T B Shima; J Torri; S Donahue; M E Lippman
Journal:  J Cell Physiol       Date:  1992-03       Impact factor: 6.384

9.  Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells.

Authors:  K Yanagihara; M Tsumuraya
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

10.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers.

Authors:  E Y Lee; H To; J Y Shew; R Bookstein; P Scully; W H Lee
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

View more
  26 in total

1.  SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas.

Authors:  Adriana Handra-Luca; Sylviane Olschwang; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2011-10-16       Impact factor: 4.064

2.  High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells.

Authors:  T A Sohn; G H Su; B Ryu; C J Yeo; S E Kern
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

3.  Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.

Authors:  E Montgomery; M Goggins; S Zhou; P Argani; R Wilentz; M Kaushal; S Booker; K Romans; P Bhargava; R Hruban; S Kern
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 4.  Molecular pathways in pancreatic carcinogenesis.

Authors:  Anne M Macgregor-Das; Christine A Iacobuzio-Donahue
Journal:  J Surg Oncol       Date:  2012-07-17       Impact factor: 3.454

5.  ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.

Authors:  G H Su; R Bansal; K M Murphy; E Montgomery; C J Yeo; R H Hruban; S E Kern
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells.

Authors:  Sang Gyun Kim; Hyun-Soon Jong; Tae-You Kim; Jung Weon Lee; Noe Kyeong Kim; Seung Hwan Hong; Yung-Jue Bang
Journal:  Mol Biol Cell       Date:  2003-10-31       Impact factor: 4.138

Review 7.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

8.  Inhibition of pancreatic carcinoma cell growth in vitro by DPC4 gene transfection.

Authors:  Wei Shen; Guo-Qing Tao; De-Chun Li; Xing-Guo Zhu; Xia Bai; Bing Cai
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

9.  TGF-beta1 attenuates mediator release and de novo Kit expression by human skin mast cells through a Smad-dependent pathway.

Authors:  Wei Zhao; Gregorio Gomez; Shao-Hua Yu; John J Ryan; Lawrence B Schwartz
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy.

Authors:  Christine A Iacobuzio-Donahue
Journal:  J Gastrointest Surg       Date:  2012-06-29       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.